title: In vitro activities of ertapenem against drug-resistant Streptococcus pneumoniae and other respiratory pathogens from 12 Asian countries.
abstract: In vitro activities of ertapenem and 11 other comparator agents were tested against 1025 isolates of respiratory pathogens collected from 12 Asian countries. Resistance rate to ertapenem was 1.2% in 602 isolates of Streptococcus pneumoniae (MIC(50), 0.06/MIC(90), 1 microg/mL). Ertapenem was also very active against penicillin-, ciprofloxacin-, erythromycin-, and multidrug-resistant pneumococcal isolates (resistance rate: 3.5%, 2.7%, 1.9%, and 2.7%, respectively). Ertapenem-resistant pneumococcal isolates were found only in Vietnam and Korea. Ertapenem resistance was not found in methicillin-susceptible Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, and Klebsiella pneumoniae, including extended-spectrum beta-lactamase producers. In vitro data suggest that ertapenem could be a useful treatment option for community-acquired pneumonia.
authors.affiliation: Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-170, Korea. jhsong@ansorp.org
authors.forename: Jae-Hoon
authors.initials: JH
authors.lastname: Song
authors.forename: Kwan Soo
authors.initials: KS
authors.lastname: Ko
authors.forename: Mi Young
authors.initials: MY
authors.lastname: Lee
authors.forename: Sulhee
authors.initials: S
authors.lastname: Park
authors.forename: Jin Yang
authors.initials: JY
authors.lastname: Baek
authors.forename: Ji-Young
authors.initials: JY
authors.lastname: Lee
authors.forename: Sang Taek
authors.initials: ST
authors.lastname: Heo
authors.forename: Ki Tae
authors.initials: KT
authors.lastname: Kwon
authors.forename: Seong Yeol
authors.initials: SY
authors.lastname: Ryu
authors.forename: Won Sup
authors.initials: WS
authors.lastname: Oh
authors.forename: Kyong Ran
authors.initials: KR
authors.lastname: Peck
authors.forename: Nam Yong
authors.initials: NY
authors.lastname: Lee
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001208:Asia / Q000453:epidemiology; D001424:Bacterial Infections / Q000453:epidemiology / Q000382:microbiology*; D024901:Drug Resistance, Multiple, Bacterial; D000077727:Ertapenem; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000201:enzymology; D016905:Gram-Negative Bacterial Infections / Q000453:epidemiology / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000453:epidemiology / Q000382:microbiology*; D018571:Sentinel Surveillance; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D001618:beta-Lactamases / Q000096:biosynthesis; D047090:beta-Lactams / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D001618:beta-Lactamases; D000077727:Ertapenem